Company Overview
RxSight, Inc. operates as a commercial-stage medical technology company dedicated to the research and development, manufacture, and sale of light adjustable intraocular lenses utilized in cataract surgery within the United States. The company functions within the Healthcare sector, specifically targeting the Medical Devices industry, where its products enable physicians to customize and enhance visual outcomes for patients undergoing ocular procedures. At its current scale, the entity commands a market capitalization of $271.95M while generating annual revenue of $134.48M, supported by a workforce of 461 employees. These valuation and revenue figures indicate that the company holds a significant position as a mid-cap entity in the specialized medical optics market, possessing substantial assets to fund its R&D initiatives and manufacturing operations despite operating losses.
Financial Health
The company reported revenue of $134.48M for the trailing twelve months, yet recorded a net income of $-38,944,000 and an EBITDA of $-44,925,000. The substantial gap between positive revenue and negative net income reveals a cost structure characterized by high operating expenses that are not fully offset by gross profitability. Free cash flow stands at $-1,625,250, which indicates that the company is currently burning cash rather than generating liquidity, suggesting a reliance on external capital sources or existing cash reserves to fund ongoing operations. When analyzing profitability margins, the gross margin is 76.6%, indicating high efficiency in converting production costs into revenue, while the operating margin is -34.8% and the profit margin is -29.0%, reflecting significant non-operating costs and losses that erode overall profitability. The balance sheet shows a cash position of $228.13M against total debt of $11.04M, resulting in a debt-to-equity ratio of 4.00, which suggests a leveraged capital structure where equity is relatively small compared to debt obligations. Despite the leverage, the current ratio is an exceptionally high 10.95, indicating robust short-term liquidity and a strong ability to cover current liabilities with available current assets. Return on Equity is -14.0% and Return on Assets is -9.6%, metrics that reveal management is currently utilizing shareholder capital and asset base to generate losses rather than positive returns.
Valuation Assessment
Valuation multiples for the company include a trailing P/E ratio of N/A due to negative earnings and a forward P/E of -1.22, implying that the market expects earnings to remain negative or for the company to reach profitability in the future. The price-to-book ratio is 0.99, which indicates that the market values the company at approximately one dollar for every dollar of net book value, suggesting no significant premium over the company's underlying asset value. Alternative valuation metrics such as a price-to-sales ratio of 2.02 and an EV/EBITDA of -1.22 suggest that investors are pricing the stock based on revenue generation rather than current earnings power or cash flow potential. Regarding price volatility, the stock has a 52-week high of $27.13 and a 52-week low of $6.32, meaning the current price sits somewhere within this range, reflecting the wide spread typical of biotech or medical device stocks with unproven commercial viability. The beta value is 1.15, which signifies that the stock price is expected to be more volatile than the broader market, moving 15% more than the market index during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is -18.9%, while earnings growth year-over-year is N/A due to the lack of prior period profitability for comparison. Since the company is currently unprofitable, it is not possible to determine if earnings are growing faster or slower than revenue, but the decline in revenue indicates a contraction in sales volume or pricing power. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that it reinvests all available earnings, or rather, its capital reserves, into growth initiatives rather than distributing income to shareholders. This profile characterizes the company as a growth-oriented entity that prioritizes expansion and product development over providing regular income to investors, relying on its substantial cash reserves to navigate the current period of negative earnings and revenue contraction.